Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixabepilone - R Pharm

X
Drug Profile

Ixabepilone - R Pharm

Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; IXEMPRA; Ixempra; NSC 710428; Patupilone analogue

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GBF
  • Developer Allarity Therapeutics; Bristol-Myers Squibb; R-Pharm; Yale University
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 21 Nov 2023 R-Pharma in collaboration with Yale university completes a phase-II clinical trial in Ovarian cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer (In the elderly, Metastatic disease, Second-line therapy or greater, In adults, Combination therapy) in USA (IV) (NCT03093155)
  • 05 Jul 2023 Efficacy data from a phase II trial in Breast cancer released by Allarity Therapeutics
  • 22 Dec 2021 Vector Pharma and R-PHARM enter into a licensing agreement to market ixabepilone for Breast cancer in Morocco, Tunisia, Algeria, Libya, Egypt, Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Lebanon, Jordan, and Iraq
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top